As the pharmaceutical industry advances toward low global warming potential (GWP) propellants like HFA152a and HFO1234ze(E), understanding material compatibility becomes critical, especially when it comes to leachables from common device components.
In a recent evaluation, a group of pulmonary experts at Kindeva assessed the extractable levels associated with various polybutylene terephthalate (PBT) suppliers in pressurized metered dose inhaler (pMDI) formulations containing ethanol and low-GWP propellants. The study was designed to simulate worst-case conditions and generate actionable insights for development teams reformulating with emerging propellant systems.
The findings reinforce the importance of careful material selection and formulation control during the transition to sustainable pMDI technologies:
- Propellant choice affects extractable levels
- Increasing ethanol concentration increases leachables
- PBT grade influences extractable output
- Oligomer presence may impact performance
Understanding the interactions between propellant, co-solvent and material grade is essential for ensuring product stability, safety and compliance as low-GWP formulations progress toward commercialization.
Curious about the full impact of propellant, ethanol and material selection on leachables? Explore the full poster presentation.
Connect with Kindeva to discover how our end-to-end expertise helps future-proof your low-GWP inhalation products by mitigating extractables risk and accelerating sustainable pMDI development.
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
What makes Bridgeton the perfect partner for your next sterile fill finish project?
The pharmaceutical sector is experiencing a significant increase in the demand for advanced biologics, biosimilar therapies and other sterile injectables. As a result, the global sterile injectables market is projected to grow from $632 billion in 2025 to $1.078 trillion by 2032, with a compound annual growth rate of 7.9% [1]. In response to this […]
Learn More
From vial to value: How GLP-1s are redefining injectable care for chronic conditions
The market for glucagon-like peptide-1 (GLP-1) therapies is growing rapidly, with a projected value of $186.6 billion by 2032. Originally developed for diabetes, these therapies are now widely used for obesity treatment, which has created a need for convenient and scalable delivery systems. This growth is reshaping the industry, creating new demands on manufacturing capacity […]
Learn More
The Kindeva Advantage: Setting the Gold Standard for Elemental Impurities Testing
In this blog, Jen Roark, Scientific Director of Injectables at Kindeva, explores the challenges of controlling elemental impurities in drug products. She breaks down the risks and regulatory guidelines outlined in USP <232> and ICH Q3D, then takes a deep dive into the findings of a recent PQRI interlaboratory study that highlights the complexities of […]
Learn More
A bridge to the future: Our world-class Bridgeton facility
Manufacturing sterile injectables today is more complex than ever. Navigating stringent aseptic requirements, evolving regulatory expectations and the need for significant specialized investment has made the path to market increasingly challenging. A fragmented approach across development, drug substance manufacturing and fill finish remains a common industry practice that can introduce critical vulnerabilities. With every handoff, […]
Learn More
Mastering USP 661.1 and 661.2: Kindeva Drug Delivery Simplifies Your Path to Compliance
Understanding the evolution of USP <661.1> and <661.2> In this blog, Jen Roark, Scientific Director of Injectables at Kindeva, breaks down the critical shift in pharmaceutical packaging standards ahead of the fast-approaching December 1, 2025, implementation deadline. She covers the history of USP <661.1> and <661.2>, the move to a risk-based framework, specific testing requirements […]
Learn More
The impact of inlet design on HFA-152a pMDI drug delivery
When assessing aerodynamic particle size distribution (APSD) using the Next Generation Impactor (NGI), throat model selection can significantly influence drug deposition outcomes. Accurate deposition data is essential for optimising pMDI design and ensuring consistent, effective drug delivery to patients. Recent research by our pulmonary/pMDI experts—Aaron Taylor, Chad Haraldson, and Stephen Stein at Kindeva—explores how United […]
Learn More
The three key trends that will most impact drug development in 2025
The speed of change in the drug development and manufacturing sector requires its stakeholders to be proactive in understanding and addressing key trends and directions the industry is taking. As a global market of considerable size and significance, the value of which is anticipated to grow from $589.06 billion in 2024 to $632.71 billion in […]
Learn More
Microneedle array patch characterization recording
Microneedle array patches (MAPs) have the potential to transform delivery of medications and vaccines. While this innovative drug delivery format could result in improved efficiency across a wide range of therapeutics, it also brings critical challenges. To successfully move from concept to commercialization, MAP manufacturers must consider scalability, regulatory compliance, and other complexities. In this […]
Learn More
Microneedle array patch characterization presentation
Microneedle array patches (MAPs) are a transformative innovation in drug delivery, with the potential to redefine how medications and vaccines reach patients. MAPs promise a simpler, more effective way to deliver a wide range of therapeutics, but their journey from concept to commercialization is filled with critical challenges. From scaling manufacturing to ensuring regulatory compliance, […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.